Navigation Links
Drug that targets vasculature growth attacks aggressive thyroid cancer
Date:5/15/2009

ORLANDO - A medication that helps stop the growth of new blood vessels has produced dramatic benefits for some patients with aggressive thyroid cancer, research from Mayo Clinic indicates.

At the annual meeting of the American Society of Clinical Oncology (ASCO), Mayo investigators report that cancer in about two-thirds of 37 patients with aggressive differentiated thyroid cancer treated with the drug pazopanib either stopped growing, or quickly shrank.

The patient responses seen to date are promising, the researchers say, because all patients had fast-growing cancers that had spread to their lungs, with half involving lymph nodes and 39 percent also involving bones.

"The benefits were striking in many patients to a degree we have not previously seen in thyroid cancer in response to other therapies, including the standard treatment of radioiodine," says Keith Bible, M.D., Ph.D., a medical oncologist and researcher who led the multicenter clinical trial funded by the National Cancer Institute. Most of the patients treated were enrolled at the Mayo Clinic campuses in Minnesota and Florida.

Approximately one-third of patients achieved sustained and dramatic benefit from pazopanib, while another one-third experienced stabilization of their cancer or some tumor shrinkage. The remaining one-third of patients did not benefit from the drug. The agent was also well tolerated by the majority of patients, Dr. Bible adds.

What is not yet known, however, is the drug's effect on overall survival. "We need more time to establish that definitively," says Dr. Bible. "The trial has been going on for just over a year, and some of our patients are still maintaining a response, while others have not been in the study long enough for us to confirm duration of response." He notes that of the 37 original trial participants, two have died one from cancer progression and another from other causes.

The National Cancer Institute estimated that 37,340 new cases of thyroid cancer would be diagnosed in 2008, with 1,590 deaths from the cancer. The cancer is much more common in women; it is the seventh most common cancer in women in the U.S. The occurrence of thyroid cancer has recently been rising.

Most thyroid cancers are of two major "differentiated" types papillary thyroid cancer (the most common, accounting for 75 percent of cases) and follicular thyroid cancer (15 percent).

Fortunately, most patients with thyroid cancer respond well to surgery and to follow-up treatment with radioiodine; even if the cancer recurs and spreads, the disease progresses slowly in most patients, Dr. Bible says. "Many patients do well for a long time without the need of additional therapy," he says. However, about 5 percent of these patients experience rapidly progressing life-threatening disease that is insensitive to radioiodine and other treatment approaches. "Until only recently, we have not had any effective therapies for such patients."

Pazopanib is an experimental agent that is also being studied in advanced kidney, ovarian and other cancers. The drug, administered in pill form, targets proteins involved in angiogenesis, the growth of new blood vessels that has a critical role in the growth and spread of tumors. The proteins that pazopanib targets include vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-kit and Ret.

Mayo investigators are also leading clinical trials to test pazopanib in two other thyroid cancer subtypes -medullary, which does not respond to radioiodine, and anaplastic, the most aggressive subtype.

Dr. Bible says plans are also under way to test pazopanib in a larger, controlled and randomized clinical trial of patients with advanced differentiated thyroid cancer. Researchers want to more accurately assess benefits and risks.


'/>"/>

Contact: Karl Oestreich
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. New Federal Legislation Targets Toxic Chemicals in Baby Bath Products
2. Chinese Pharma Market Continues to Grow at a 5-7% Rate in 2009; AMDL Remains on Track to Meet FY09 Financial Targets
3. AMDL, Inc. Reports 2008 Year End Financial Results and Fiscal Year 2009 Financial Targets
4. Biotech company cofounded by BIDMC scientists targets natural killer T-cells
5. Stimulus Spending Targets Modernization of the Nation's Research Infrastructure
6. Waters and LabVantage Partnership Targets Laboratory Informatics Integration to Maximize Data Management and Quality of Work
7. Scientists Discover New Drug Targets for Crohns Disease
8. New bubble targets only cancer cells
9. OHSU vaccine research targets HIV in the slower, early stage of infection
10. Nanoparticle smart bomb targets drug delivery to cancer cells
11. NHHF Scholarship Program Targets Growing Demand for Diversity Among Health Care Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
(Date:6/23/2016)... Pa. , June 23, 2016 The ... in an outpatient dialysis facility.  Treatments are usually 3 ... 6 hours per visit, including travel time, equipment preparation ... a patient, but especially grueling for patients who are ... of a skilled nursing and rehabilitation centers for some ...
Breaking Medicine Technology: